Konrad, the whole USP of scancells approach is that it is being advertised as being largely effective against the vast majority of mutations so this latest mutation (as far as scancells testing period is concerned) couldn’t have come at a better time.
As long as it does what we have been told It can do in the clinical trials then it will showcase to the world what a massive advantage they have over the current vaccines and future mutations.
Just imagine the world wide cost savings if the major pharmaceutical companies don’t have to change their vaccines every 4 to 8 months.
That’s hundreds of billions saved, not to mention the cheap manufacture and storage costs.
Hasiba if that were the case then then why can’t anyone get quotes to buy any decent amounts?
It has all the hallmarks of the market makers being caught short and trying their best to balance their books.
Seen it time and time again just before a big bounce, thats why I have loaded up again today.
Good luck.
Interesting development and seems to be at odds with previous variations
https://www.bloomberg.com/news/articles/2021-11-29/young-kids-make-up-10-of-hospital-cases-in-omicron-epicenter?srnd=premium-europe
The Bloomberg link is subscription only here’s a different one
https://www.express.co.uk/news/uk/1528455/covid-live-UK-omicron-lockdown-variant-cases-G7-vaccine-latest